Table of Contents The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis Nippon India PHARMA Fund - G
Scheme Objective
CAGR return of 20.8% since its launch. Ranked 35 in Sectoral category. Return for 2019 was 1.7% , 2018 was 3.6% and 2017 was 7.6% . NAV as on 3 Aug 20 ₹211.867 ↑ 0.65 (0.31 %) Net Assets (AUM) as on 30 Jun 2020 ₹3,093 Cr. Launch Date 5 Jun 2004 Category Equity - Sectoral Rating ☆☆ Type Open Ended Fund Risk High AMC Nippon Life Asset Management Ltd. Alpha Ratio 6.16 Expense Ratio 2.33 % Sharpe Ratio 1.066 Information Ratio 1.37 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹100 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 3 Aug 20 Duration Returns 1 Month 11.5% 3 Month 17.9% 6 Month 36% 1 Year 54.4% 3 Year 18.3% 5 Year 8.5% 10 Year 15 Year Since launch 20.8% Historical Annual Returns
Year Returns 2019 1.7% 2018 3.6% 2017 7.6% 2016 -10.6% 2015 19.4% 2014 49.5% 2013 20.9% 2012 34.8% 2011 -11% Growth of 10k Over Years
Date Value 31 Jul 15 ₹10,000 31 Jul 16 ₹10,052 31 Jul 17 ₹9,187 31 Jul 18 ₹10,373 31 Jul 19 ₹9,840 31 Jul 20 ₹14,980 
Asset Allocation
Asset Class Value Cash 1.94% Equity 98.06% 
Sector Allocation
Sector Value Health Care 98.06% 
Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Dec 15 | AUROPHARMADrug Manufacturers - Specialty & Generic 10% ₹324 Cr 4,200,000
↓ -600,000 Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 500087Drug Manufacturers - General 10% ₹307 Cr 4,800,000 Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMADrug Manufacturers - Specialty & Generic 10% ₹298 Cr 6,300,976 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | 500124Drug Manufacturers - Specialty & Generic 10% ₹294 Cr 745,000 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257Drug Manufacturers - Specialty & Generic 9% ₹292 Cr 3,200,025
↑ 400,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLABDrug Manufacturers - Specialty & Generic 8% ₹239 Cr 1,050,075
↓ -50,000 Syngene International Ltd (Healthcare)
Equity, Since 30 Nov 17 | 539268Biotechnology 6% ₹196 Cr 4,894,751
↑ 96,000 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Aug 18 | 532843Medical Care Facilities 6% ₹176 Cr 14,403,541
↑ 3,800,000 Sanofi India Ltd (Healthcare)
Equity, Since 30 Jun 04 | 500674Drug Manufacturers - General 4% ₹138 Cr 175,000 Thyrocare Technologies Ltd (Healthcare)
Equity, Since 31 May 16 | THYROCAREDiagnostics & Research 4% ₹130 Cr 2,551,512
↑ 12,000
Talk to our investment specialistFund Managers
Name Since Tenure Sailesh Raj Bhan 1 Apr 05 15.26 Yr. Kinjal Desai 25 May 18 2.1 Yr. Custodians
Company Address Deutsche Bank AG Deutsche Bank AG,Kodak House, 22, D.N. Road, Registrar & Transfer Agent
KFin Technologies Private Limited Address "KARVY HOUSE",46, Avenue 4, Street No.1,,Banjara Hills, FAX 91-40-23311968 Email mailmanager@karvy.com Administrator Companies
Company Address Nippon India Mutual Fund 9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051 Auditors
Company Address Haribhakti & Co. Chartered Accountants 42, Free Press House,4th Floor,,215, Nariman Point, All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year Nippon India Pharma Fund
Normal Dividend, Payout ₹66.6556
↑ 0.21 34.65 % 52.94 % 17.49 % 8.02 % Nippon India Pharma Fund
Normal Dividend, Reinvestment ₹66.6556
↑ 0.21 34.65 % 52.94 % 17.49 % 8.02 % Nippon India Pharma Fund
Growth ₹211.867
↑ 0.65 35.98 % 54.44 % 18.28 % 8.45 % Data as on 3 Aug 20
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.
AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153
Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.
©2020 Shepard Technologies Private Limited. All Rights Reserved